AzTrials
AzTrials

Infectious KeratitisNCT06364878

Non-invasive Diagnostics of Microbial Keratitis

An observational study of Infectious Keratitis, run by Sorlandet Hospital HF at 1 site in Norway.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Infectious keratitis is a significant cause of partial vision loss and blindness and places a large burden on eye care professionals. One of the main challenges for the ophthalmologist when presented with a case of suspected microbial keratitis is the determination of the subtype of keratitis. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Infectious Keratitis
What is being tested?
In vivo confocal microscopy and Tear film sampling
How many people
125 participants
Where
1 siteNorway
Study dates
23 Aug 2023to 8 Apr 2028
How long will I take part?
3 Months
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Adult, Older adult

Study population: Patients with clinically suspected infectious keratitis, over 18 years of age, presenting to the ophthalmology department at Arendal hospital.

Who may be able to join

  • Clinically suspected infectious keratitis in patients over 18 years of age
  • Patients with acceptable travel distance to the hospital
  • Patients accepting to be part of the study

Who cannot join

  • Previously diagnosed infectious keratitis during the last 6 months
  • Over 50 percent thinning of the cornea
  • Previous use of antibiotics (other than Chloramphenicol)

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Norway1 site, 1 recruiting
  • Sorlandet hospital

    Arendal

    Neil Lagali

    Recruiting

Other trials in Norway

About this study

Official title: New Non-invasive Cellular and Molecular Diagnostics of Microbial Keratitis

Infectious keratitis is a significant cause of partial vision loss and blindness and places a large burden on eye care professionals. One of the main challenges for the ophthalmologist when presented with a case of suspected microbial keratitis is the determination of the subtype of keratitis. It must be determined whether the origin of the infection is bacterial, viral, fungal, or parasitic, in order to prescribe a correct, effective treatment aimed at the causative pathogen. In daily practice this can be challenging, and general treatments with antibiotics are prescribed. Some cases then experiences deterioration, resulting in more patients visits and further rounds of invasive treatments and progressive vision deterioration.

This project is designed to break this cycle of nonspecific diagnosis, suboptimal treatment, and progressive worsening of vision with increased interventions. New, advanced diagnostics will be brought into the clinic to provide additional information which, if our hypothesis is correct, will result in more rapid and accurate diagnosis of the keratitis subtype. This will translate into earlier administration of a more targeted treatment, avoiding the repeated round of non-targeted treatment and progressive worsening of the patient's vision. This can directly reduce to number of clinic visits and specialist time required for treatment and follow-up of keratitis, knowledge of how the eye responds to various microbes by initiating a specific cascade of molecular inflammatory signals and changes in protein expression in the tear film.

Read more

Using in vivo confocal microscopy (IVCM) we will document the cellular status of the cornea and identify microbes infecting the cornea in real-time. Secondly, tear samples will be obtained from patients with keratitis to evaluate and quantify the molecular cytokine signatures associated with specific microbial species, confirmed by microbiological culture. We will for the first time develop cytokine profiles for the various types of infection, identifying diagnostic cytokines which in the longer term can lead to development of rapid point-of-care biomarker diagnostics.

The project aims are translated into the following hypotheses:

H1: In vivo confocal microscopy imaging features detect microbial keratitis consistent with clinical assessment and outcome at a greater frequency than microbiological culture results.

H2: Cytokine profiles (or a subset of molecules) in the eye are specific for viral, bacterial, fungal, or amoebic keratitis; and H3: A combination of in vivo confocal microscopy and molecular profiling of the tear film can yield a specific keratitis diagnosis closely matching the clinical progression and outcome of keratitis.

Being tested
In vivo confocal microscopy, Tear film sampling

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • In vivo confocal microscopyDiagnostic test

    Also called IVCM

    The patients cornea will be examined non-invasively by IVCM

  • Tear film samplingDiagnostic test

    Patients tear film will be collected and stored at -80 degrees for analysis

Study groups in NCT06364878
Study groupRoleWhat they receive
Patents with suspected infectious keratitisNot described
Receives: Diagnostic Test: In vivo confocal microscopy; Diagnostic Test: Tear film sampling
Healthy controlsNot described
Receives: Diagnostic Test: In vivo confocal microscopy; Diagnostic Test: Tear film sampling

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. IVCM findings and cytokine profile in infectious keratitis is specific for the different microbial subtypes.

    A combination of in vivo confocal microscopy and molecular profiling of the tear film can yield a specific keratitis diagnosis closely matching the clinical progression and outcome of keratitis.

    Measured: 18 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Apr 2024
  2. Study start23 Aug 2023
  3. Primary completion1 Mar 2025 (estimated)
  4. Study completion8 Apr 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
125 participants (estimated)
Target duration
3 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT06364878
Sponsor's protocol ID
813533
Status last verified
Apr 2023
First submitted
10 Apr 2024
Last updated
15 Apr 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Currently there is not a plan to share individual data outside the project group due to confidentiality. If the investigators later would want to do this, new applications to the correct boards are needed.

Questions about this trial

What is this clinical trial studying?

An observational study of Infectious Keratitis, run by Sorlandet Hospital HF at 1 site in Norway.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 15 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Ingvild M Bakken (37014856, ingvild.mygland.bakken@sshf.no), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

IVCM findings and cytokine profile in infectious keratitis is specific for the different microbial subtypes. (time frame: 18 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Apr 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in